Drug Trial Radar · NCT00735462
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Last checked: Nov 20, 2026Latest source record: Jul 20, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
511
Actual
Start
Aug 2008
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Graceway Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the creams. External genital and perianal warts are caused by the infection of human papillomavirus or HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like small flesh-colored, pink, or red growths on or around the external skin of sex organs or perianal area. The warts may look similar to the small parts of a cauliflower or they may be very tiny and difficult to see. They often appear in clusters of three or four, and may grow and spread rapidly. They usually are not painful, although they may cause mild pain, bleeding, and itching.
Conditions
- Genital Warts
Interventions
2.5% imiquimod creamDrug
2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
3.75% imiquimod creamDrug
3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
Placebo creamDrug
Placebo cream applied daily to wart areas for up to 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.Time frame: Up to 16 weeks
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
NEA Clinic
Jonesboro, Arkansas
Northern Claifornia Research
Carmichael, California
California State University - Chico
Chico, California
Dermatology Research Associates
Los Angeles, California
Conant Foundation
San Francisco, California
Downtown Women's Healthcare
Denver, Colorado
Altus Research
Lake Worth, Florida
PMI Health Research Group
Atlanta, Georgia
Atlanta Women's Research Institute
Atlanta, Georgia
Altman Dermatology Associates
Arlington Heights, Illinois
Howard Brown
Chicago, Illinois
Valley Medical Center
Flint, Michigan
Women's OB/GYN
Saginaw, Michigan
Clayton Research Institute
St Louis, Missouri
Women's Health Research Center
Lawrenceville, New Jersey
Alliance Women's Research
Riverside Park, New Jersey
Southwest Clinical Research
Albuquerque, New Mexico
University Urology Associates
New York, New York
Boro Park ObGyn
New York, New York
Crescent Medical Research
Salisbury, North Carolina
Piedmont Medical Research
Winston-Salem, North Carolina
Rapid Medical Research
Cleveland, Ohio
Complete Healthcare for Women
Columbus, Ohio
Wright State University
Dayton, Ohio
Heartland Health Institute
Tulsa, Oklahoma
Clinical Trials of America
Eugene, Oregon
Westover Heights Clinic
Portland, Oregon
The Clinical Trial Center
Jenkintown, Pennsylvania
Palmetto Clinical Research
Greer, South Carolina
Alpha Clinical Research
Clarksville, Tennessee
Adams Patterson Gynecology and Obstetrics
Memphis, Tennessee
Tennessee Women's Care
Nashville, Tennessee
DiscoveResearch
Bryan, Texas
TMC Life Research
Houston, Texas
West Houston Clinical Research Services
Houston, Texas
Urology San Antonio Research
San Antonio, Texas
The Center for Clinical Studies
Webster, Texas
Utah Clinical Trials
Salt Lake City, Utah
Wasatch Clinical Research
Salt Lake City, Utah
CARE-ID
Annandale, Virginia
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.